Dr. Qiang Liu: Can Triple-Negative Breast Cancer Be Treated Without Chemotherapy?—Exploring Precision Medicine Guided by Biomarkers in Breast Cancer
In recent years, significant advancements have been made in the treatment of triple-negative breast cancer (TNBC), particularly in the field of biomarker research. To delve deeper into this, Cancer Outlook invited Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University to provide an in-depth analysis of two recent landmark studies. These studies explore the prognostic value of tumor-infiltrating lymphocytes (TILs) in early-stage TNBC patients who have not undergone chemotherapy. The findings from these studies reveal a correlation between TIL levels and patient survival, offering a new perspective for identifying patients with a good prognosis who may not require chemotherapy. Additionally, Professor Liu shares insights from his own research on circulating tumor DNA (ctDNA) in breast cancer treatment, underscoring the importance of precision medicine in managing TNBC.









